A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.
Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...
RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback